U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07335887) titled 'Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis' on Dec. 14, 2025.
Brief Summary: The goal of this study is to evaluate the efficacy and safety of Sonrotoclax combined Regimen in patients with t(11;14) AL amyloidosis. Participants will receive the Sonrotoclax Plus Dexamethasone regimen with or without Daratumumab for 12 cycles. The Hematologic Response, Organ Response, Survival, and Safety will be evaluated.
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
AL Amyloidosis (AL)
t(11;14) Positive
Intervention:
DRUG: sonrotoclax
t(11;14) AL amyloid...